Efficacy of an Adapted Antibiotherapy in Hurley Stage 2 Hidradenitis Suppurativa Patients

Inclusion Criteria: * Adults \< 60 years old * Diagnosis of HS according to European Dermatology guidelines: * Recurrent inflammation occurring more than 2 times in the past 6 months in the inverse regions of the body, presenting with nodules, sinus-tracts and/or scarring. * Signs: Involvement of axilla, genitofemoral area, perineum, gluteal area (and infra-mammary areafor women). Presence of nodules (inflamed or noninflamed), sinus tracts (inflamed or noninflamed), abscesses, scarring (atrophic, mesh-like, red, hypertrophic or linear) * Active HS with i) ≥ 1 year of evolution and ii) ≥ 4 flares during the previous year * Clinical severity of HS at inclusion: Hurley stage 2 * BMI \< 35 * Written informed consent from patient * Patient able to complete DLQI * Patients affiliated to the French health system (Assurance Maladie), except French state medical aid beneficiaries (Aide Médicale d'Etat) * Active compatible contraception for men and women of childbearing or inability to procreate * Available laboratory blood test performed within the last 2-months Non inclusion Criteria: * Person \< 18 and ≥ 60 years old * Former stage 3 HS * Previous use of the experimental treatment * Unauthorized drugs for the study during the month preceding the inclusion * Any contra-indication to study treatments or excipient (e.g. lactose, cornstarch, riboflavin notably): pregnancy, breastfeeding, known allergy to experimental or reference drugs, wheat allergy, tendinopathy, QT prolongation, bradycardia, heart failure, heart rhythm disturbances, hydroelectrolytic disorders, hypokalemia, coagulation disorders, severe liver/kidney dysfunction, porphyria, mandatory use of nonsteroidal anti-inflammatory drugs (NSAIDs) for other medical conditions * Unbalanced diabetes (ie HbA1c above 7%) * Dysphagia, untreated gastro-oesophageal reflux/ulcer * BMI ≥ 35 * Immune suppression, inflammatory disease, including gastroenterologic and rheumatologic inflammatory conditions * Lactase deficiency, lactose and galactose intolerance * Malabsorption syndrome * Person living in the same household as another patient * Person under guardianship or curatorship * Individuals with any condition which, in the opinion of the investigator, might interfere with the evaluation of the study objectives (e.g patient unable to complete DLQI, or poor predictable observance * Participation in another interventional research on health products studies * Patients requiring repeated (more than 3/year) use of antibiotics for a chronic disease other than HS * Alcohol-dependant patients defined as an addiction to alcohol with a negative impact on health, social or personal life Exclusion criteria: Pregnancy QT prolongation Abnormal result of routine lab tests corresponding to contra-indication to study treatments Unauthorized drug for the study during all the study (from study treatments interactions listed in the SmPC, Cf. unauthorized drug listed in non-inclusion criteria). Development of hypersensitivity to any of the study products and/or excipients (e.g. lactose, corn starch, riboflavin).